Drugs / polyethylene glycol plus ascorbate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01689792 | Nov 2011 → Jan 2013 | colorectal cancer | Norgine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2018-10-22 | Norgine | Results PLENVU® (NER1006) the first 1 litre bowel preparation to show superior high-quality segmental cleansing of the colon compared to standard of care norgine.com ↗ |
| 2018-07-19 | Norgine | Results Endoscopy publishes the MORA phase III trial for PLENVU® (NER1006), the only 1 LITRE PEG based bowel preparation[i] norgine.com ↗
PLENVU® is the first low volume preparation to demonstrate superior colon cleansing efficacy versus MOVIPREP®, with comparable safety and tolerability. |
| 2018-05-07 | Norgine | Regulatory Norgine announces US FDA approval for PLENVU® (NER1006) – 1 LITRE PEG based bowel cleansing preparation for colonoscopy norgine.com ↗
Norgine B.V. today announced that the US Food and Drug Administration (FDA) has approved PLENVU® (NER1006), an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. |
| 2018-02-22 | Norgine | Results Positive new data show superiority of PLENVU® (1 LITRE PEG preparation) compared to MOVIPREP® (2 LITRE PEG + ASCORBATE) norgine.com ↗
This post hoc analysis of the MORA phase III study, assessed PLENVU® cleansing efficacy versus MOVIPREP® in both the overall colon and the right colon, using mean Boston Bowel Preparation Scale (BBPS) Scores. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polyethylene glycol plus ascorbate | “Efficacy of two low volume bowel cleansing preparations, polyethylene glycol plus ascorbate (PEG + Asc) and sodium picosulfate/magnesium citrate (NaPic/MgCit), were compared...” PMID 25950434 ↗ May 2015 |
| Known as | MOVIPREP | “Norgine, the manufacturer of MOVIPREP (PEG+Asc), whose company funded this study.” PMID 25950434 ↗ May 2015 |